Navigation Links
Nano Mask Names Dr. Hassan Bennani to Board of Directors
Date:1/24/2013

FISHKILL, N.Y., Jan. 24, 2013 /PRNewswire/ -- Nano Mask, Inc., (PINKSHEETS: NANM), a materials technology development company focused on health and wellness related markets, today announced that it has appointed Hassan Bennani , MD, to its Board of Directors.

Dr. Bennani is the co-founder and CEO of KellBenx, Incorporated, a closely held Long Island, NY based biotechnology company focused on women's healthcare, concentrating on the development of a patented breakthrough non-invasive prenatal diagnostic (NIPD) for analyzing genetic disorders and a patent pending breakthrough test to determine a woman's risk of preterm delivery.

Dr. Bennani was previously the head of business development at Lenetix, a women's health focused lab acquired by Bio-Reference Laboratories.  Prior to that, Dr. Bennani was a Vice President of Sales and Marketing for Adeza Biomedical Corporation, which was acquired by Hologic.  

"I am excited about joining forces with Nano Mask , which has assembled an impressive hospital textile product portfolio that can grow its sales significantly over the next few years," said Dr. Bennani, who went on to add, "I am confident that the industry contacts that I have made over the course of my career, especially in international markets, will be very receptive to Nano Mask 's products."

"Dr. Bennani's extensive experience and network make him ideally suited to help promote our products both in the United States and internationally," said Edward Suydam , President and CEO, Nano Mask Inc.

About Nano Mask , Inc.

We are a healthcare product development and distribution company providing innovative and cost effective emergency and critical care and infection control products to a variety of market segments within the healthcare industry. Our customers range from hospitals, emergency services, surgery centers, long-term care facilities, nursing homes and other clinical settings throughout the healthcare continuum.

Forward-looking Statement

This release may contain statements that are forward-looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. Specifically, any unforeseen delays in manufacturing and distribution may affect sales of NMI products. NMI does not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. The actual future plans and results of the company could differ significantly from such forward-looking statements.

Contact:

For further information:
Ed Suydam (914) 760-7857 eds@nmihealth.com

 

 

 

 


'/>"/>
SOURCE Nano Mask , Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. SPIE Names 69 New Fellows of the Society in 2013
2. PathoGenetix Names Ann Merrifield as Chief Executive Officer and Prepares to Launch Unique Bacterial Identification Technology
3. AtheroNova Names New Director
4. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
5. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
6. Islet Sciences Names Richard A. Franco, Sr. to its Board of Directors
7. Elsevier / MEDai Names Dr. Peter Edelstein as Chief Medical Officer and Dr. Gerald Osband as Director of Product Strategy
8. PharmaVOICE Names Four inVentiv Health Associates Among "100 Most Inspiring" Leaders in Healthcare
9. Lloyd Library and Museum Names ABCs Blumenthal to New Honorary Advisory Board
10. Ethical Corporation Names Life Technologies First CSO Sustainability Executive of the Year
11. Triple-S Management Corporation Announces the Retirement of Socorro Rivas-Rodriguez; Names Pablo Almodovar Scalley as Successor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 2017  If only one in every hundred ... resistance to chemotherapy, thousands of cancer cells would ... on finding these mutations in ever-smaller subpopulations of ... DNA in blood — to guide treatment decisions ... Unfortunately, however, detecting these genetic anomalies may be ...
(Date:2/16/2017)... Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing the power ... triple negative breast cancer (TNBC), announced today their completion of ... The YEi Start in France ... their business in France and Europe.  ... complete an intensive one week immersion in France ...
(Date:2/16/2017)... ANGELES , Feb. 16, 2017   ... ), a clinical-stage biotechnology company developing first-in-class biological ... announced that it has elected to terminate its ... natriuretic peptide receptor agonists, including Cenderitide. ... strategic move as we prioritize our efforts to ...
(Date:2/16/2017)... 2017  Champions Oncology, Inc. (NASDAQ: CSBR ... of advanced technology solutions and products to personalize the ... addition of new cohorts of PDX models to their ... expand Champions, product line in hepatocellular cancer, breast cancer, ... and non-small cell lung cancer (including EGFR mutation; ALK/ROS1 ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, will present at the LEERINK Partners 6th ... Palace Hotel on Wednesday, February 15, 2017 at 10 ... of the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh ... the conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
Breaking Biology News(10 mins):